Skip to main content
. Author manuscript; available in PMC: 2020 Dec 21.
Published in final edited form as: Urol Oncol. 2019 Aug 6;37(10):688–695. doi: 10.1016/j.urolonc.2019.05.017

Table 1:

Model Inputs, including costs and utility values, with base case variables, range, and type of distribution used in sensitivity analyses

Variable Value Minimum Maximum Reference Distribution
Utility Values
SD on AA or ADT alone 0.83 0.83 1 (AA only) Chi 201812 N/A
SD on DCT 0.78 N/A N/A Morgans 201811 N/A
Post-DCT recovery state# 0.78–0.83 N/A N/A Morgans 201811 N/A
Fatigue 0.78 N/A 0.95 (when AA=1) Bayoumi 200013 N/A
Febrile Neutropenia 0.47 N/A N/A Younis 201114 N/A
Progression/Death 0 N/A N/A N/A
Progressed Disease (sensitivity model to death only) 0.725 N/A N/A Zhong 201315 N/A
Survival probability at 2 years*
ADT 33% 26% (HR=1.2) 41% (HR=0.85) CHAARTED, LATITUDE5,7 Normal (log-HR)
DCT 51% 46% (HR=1.2) 58% (HR=0.85) CHAARTED5 Normal (log-HR)
AA 61% 55% (HR=1.2) 67% (HR=0.85) LATITUDE7 Normal (log-HR)
AE rates
DCT discontinuation 0.12 N/A N/A CHAARTED5 N/A
AA discontinuation 0.12 N/A N/A LATITUDE7 N/A
Fatigue (ADT) 0.01 N/A N/A LATITUDE7 N/A
Fatigue (AA) 0.02 N/A N/A LATITUDE7 N/A
Neutropenia (DCT) 0.121 0.089 0.157 CHAARTED5 Binomial
Febrile Neutropenia (DCT) 0.061 0.04 0.09 CHAARTED5 Binomial
Costs (USD)
Drugs/Routine
ADT (q3 month) 1115 612 1343 Access Pharmacy,16 VA22 Gamma
ADT non-drug costs (per cycle)Δ 137 N/A N/A CMS18,19 N/A
AA (per month) 9368 5550 11275 Access Pharmacy,16 VA22 Gamma
AA non-drug costs (per cycle)Δ 151 N/A N/A CMS18,19 N/A
DCT (per 3 wk cycle) 1576 266 1710 Access Pharmacy,16 VA22 Gamma
DCT non-drug costs (per cycle)Δ 374 (on trt)/
142 (post-trt)		 N/A N/A CMS18,19 N/A
AEs
Neutropenia$ 5937 3579 7149 Access Pharmacy,16 VA22 Gamma
Febrile neutropenia 18507 5843 29217 Lyman 200920 Gamma
#

Assumes linear gain between utility on treatment and after recovery, with full recovery at 12 months from treatment start

*

Cycle-specific probabilities calculated based on full curves and hazard ratios, 2-year survival probabilities included here to illustrate effects

$

Cost of peg-filgrastim plus administration

Δ

Includes medication administration, physician visits, routine labs, imaging